2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2343 LDH is an incomplete surrogate for tumor burden and predicts efficacy and neurotoxicity through different components in CAR T-cell therapy

Alaa Ali, MD, Aleksandr Lazaryan, MD MPH PhD2, Rawan Faramand, MD3, Doris K. Hansen, MD4, Nima Ghalehsari, MD5, Taiga Nishihori, MD6, Farhad Khimani, MD7, Sayeef Mirza, BS, MPH, MD8, Sameh Gaballa, MD9, Dilan Anil Patel, MD10, Hien Liu, MD11, Yoganand Balagurunathan, PhD12, Jongphil Kim, PhD13, Nicholas Figura, MD14, Fabiana Perna, MD, PhD15, Bijal Shah, MD, MS16, Kieron Dunleavy I, MD17, Michael D. Jain, MD, PhD18, Frederick L. Locke, MD19
1 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 Washington University In Saint Louis, Saint Louis, Missouri, United States
11 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
17 Medstar Georgetown University Hospital, Washington, District of Columbia, United States
18 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
19 Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Introduction: Lactate dehydrogenase (LDH) is widely used in lymphoma as a surrogate for tumor burden and is a component of the International Prognostic Index (IPI); elevated pre-infusion LDH is a consistently reported baseline predictor of inferior survival after CD19 CAR T-cell therapy. Yet LDH is nonspecific and has never been benchmarked against a direct volumetric measure of burden. Metabolic tumor volume (MTV) on [18F]FDG PET/CT provides that reference: high baseline MTV consistently predicts inferior survival after CAR T-cell therapy (pooled hazard ratio 2.1 for overall survival across 15 studies). In axicabtagene ciloleucel (axi-cel)-treated large B-cell lymphoma (LBCL), a setting in which both efficacy and neurotoxicity are burden-associated, we asked how closely LDH tracks MTV, what its burden-independent variation measures, and whether LDH and MTV predict efficacy and toxicity differently.

Methods: Baseline LDH and MTV (manually segmented on 18F-FDG PET/CT at 41% of lesion SUVmax, liver-referenced) were paired in 100 discovery patients (25 severe [grade ≥3] ICANS, 12 severe cytokine release syndrome [CRS], 49 complete responses, 62 progression-free survival [PFS] events); angiopoietins were available in 66. LDH was split by log-log regression into an MTV-explained and a burden-independent (residual) component. Analyses used Spearman and partial correlations, and ordinal proportional-odds models (CRS and ICANS severity). LDH's efficacy and toxicity signals were externally tested in a registry cohort (axi-cel, 2021+, n=261).

Results: LDH correlated strongly with MTV (Spearman rho=0.71) but explained only 45% of the variance in log LDH (Pearson r2=0.45). The two measures differed sharply in range: MTV spanned ~890-fold across patients (1.5-1334 mL) while LDH spanned only 15-fold (127-1924 U/L). LDH also tracked burden sub-proportionally, remaining nearly flat across the lowest three MTV quartiles (median 193, 224, 268 U/L) and rising only in the highest (606 U/L). A doubling of LDH corresponded to a roughly four-fold increase in tumor volume (allometric slope 2.11). Across stage, IPI category, and bulky versus non-bulky disease, both markers rose with clinical burden, but MTV separated the strata far more sharply (e.g. bulky versus non-bulky: 7.5-fold for MTV vs 1.3-fold for LDH). LDH and MTV disagreed in 24% of patients (kappa = 0.52). The discordance was not random: complete response was worst when both markers were high (18%) and best when both were low (76%), with severe ICANS following the same gradient (33% vs 13%). Patients with high LDH but low MTV were enriched for non-GCB disease (42%) and a severe ICANS rate of 34%, whereas those with low LDH but high MTV carried the most bulky disease (33%).

Head-to-head, the two markers dissociated by outcome. For PFS, MTV retained its effect when both were entered (HR 1.67 per SD) while LDH fell to null (1.11); for ICANS severity the pattern reversed (LDH OR 1.89; MTV 1.01). CRS was weakly predicted by either.  

By decomposition, LDH's PFS signal was carried entirely by its burden component (HR 1.79) and its ICANS signal by both the burden (OR 1.56) and the burden-independent (1.61) components. The LDH component unexplained by tumor volume, which carried the ICANS signal, appeared to be endothelial: it tracked the Ang-2/Ang-1 balance (Ang-2 p = 0.03, Ang-1 p = 0.006 in a joint model), and adjusting for the ratio attenuated the residual-LDH association with ICANS by 31% (OR 1.78 to 1.48, to non-significance) while the ratio itself remained predictive (proportional-odds OR 1.69, p=0.04). In an independent cohort of 261 axi-cel-treated patients, LDH's efficacy signal replicated with no significant heterogeneity (validation PFS HR 1.75 per SD, 95% CI 1.48-2.07, p<0.001; discovery HR 1.51, 1.21-1.88; I2=14%, non-significant), whereas its ICANS signal, though still detectable, attenuated substantially (OR 1.91 to 1.27; AUC 0.57; I2= 69%).

Conclusions: In axi-cel-treated LBCL, LDH is a compressed and incomplete surrogate for tumor burden, misclassifying burden in roughly one patient in four. Its predictive value dissociates by endpoint: LDH's efficacy signal is carried entirely by burden and is reproducible in an independent cohort, while MTV, as the direct measure of that burden, is the stronger predictor. Its neurotoxicity signal, by contrast, derives in part from a burden-independent component that appears endothelial and is less reproducible.

Alaa Ali, MD: Kite Pharma - Consultancy (Includes expert testimony)